Wall Street Zen Upgrades BioAge Labs (NASDAQ:BIOA) to Hold

BioAge Labs (NASDAQ:BIOA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. Citigroup boosted their price objective on shares of BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioAge Labs currently has a consensus rating of “Hold” and an average price target of $15.00.

BioAge Labs Trading Down 6.3%

BioAge Labs stock opened at $20.16 on Friday. BioAge Labs has a 12-month low of $2.88 and a 12-month high of $24.00. The stock has a market cap of $722.74 million, a P/E ratio of -13.26 and a beta of 1.38. The company has a fifty day simple moving average of $12.47 and a 200-day simple moving average of $7.80.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $2.05 million during the quarter.

Insiders Place Their Bets

In related news, insider Paul D. Rubin sold 68,897 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $10.19, for a total value of $702,060.43. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Kristen Fortney sold 233,107 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the sale, the chief executive officer directly owned 976,949 shares of the company’s stock, valued at $17,702,315.88. This represents a 19.26% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 347,004 shares of company stock worth $5,673,859. Insiders own 20.82% of the company’s stock.

Institutional Trading of BioAge Labs

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after purchasing an additional 93,694 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of BioAge Labs by 60.8% during the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after purchasing an additional 171,426 shares during the last quarter. Millennium Management LLC lifted its holdings in BioAge Labs by 749.8% in the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after acquiring an additional 270,479 shares during the period. Marshall Wace LLP increased its position in BioAge Labs by 324.7% in the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after buying an additional 173,388 shares in the last quarter. Finally, Stonepine Capital Management LLC lifted its position in shares of BioAge Labs by 202.2% in the second quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after acquiring an additional 101,085 shares in the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.